FR 2021-03448

The document presents an amended notice regarding a change in the meeting schedule for the Cancer Etiology Study Section, facilitated by the National Institutes of Health (NIH). Initially, the meeting was set for March 1, 2021, but it has been rescheduled to March 2, 2021, maintaining the same hours from 10:00 a.m. to 5:00 p.m. The modification was formally communicated on February 16, 2021, and the earlier notice was published in the Federal Register on February 4, 2021.

General Summary

The primary purpose of this document is to inform about a change in the date of the Cancer Etiology Study Section meeting under the auspices of the NIH. While the meeting's date has been altered, the start and end time remain unchanged, and it will continue to be a closed session not open to the public. Such details are essential for those involved to adjust their schedules adequately.

Significant Issues or Concerns

The document provides limited information regarding the rationale behind the change in the meeting date from March 1 to March 2. This lack of context might concern stakeholders who need to understand the necessity and implications of such scheduling changes. Additionally, there is no mention of the meeting's agenda or the topics to be discussed, which could hinder assessments of its importance or relevance.

Another point of concern is the meeting's closed nature, without elaborate explanation. Transparency is a crucial factor for public entities like the NIH, and not having the reason for closure could evoke difficulties regarding public trust and accountability.

Impact on the Public and Stakeholders

Broad Public Impact

For the general public, the rescheduling of a specific study section meeting might have minimal direct impact. However, for those particularly interested in the activities of the NIH or its research directions, understanding such meetings' proceedings can be vital. The absence of explanation on why the meeting is closed may foster a view of opacity, thereby affecting public perception of NIH’s transparency.

Impact on Specific Stakeholders

For individuals directly involved or interested in cancer research, particularly focused on cancer etiology, this meeting is significant. Researchers, grant applicants, and scientific professionals are likely stakeholders who might be affected by the timing of this notice. The change in schedule requires these participants to be attentive and adapt their plans accordingly. Since the meeting is closed, it may limit immediate access to potentially pivotal discussions and directions regarding cancer etiology, thereby affecting the flow of information in this scientific community.

In conclusion, while the amended notice serves a fundamental purpose of updating interested parties about a schedule change, the lack of detailed justification and absence of transparency regarding the meeting's closure may inadvertently raise concerns among stakeholders and the general public. More comprehensive communication could enhance understanding and foster a greater sense of trust in the processes undertaken by the NIH.